Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,974 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rationale and design of the RIACT-study: a multi-center placebo controlled double blind study to test the efficacy of RItuximab in Acute Cellular tubulointerstitial rejection with B-cell infiltrates in renal Transplant patients: study protocol for a randomized controlled trial.
Schiffer L, Schiffer M, Merkel S, Schwarz A, Mengel M, Jürgens C, Schroeder C, Zoerner AA, Püllmann K, Bröcker V, Becker JU, Dämmrich ME, Träder J, Grosshennig A, Biertz F, Haller H, Koch A, Gwinner W. Schiffer L, et al. Among authors: koch a. Trials. 2012 Oct 26;13:199. doi: 10.1186/1745-6215-13-199. Trials. 2012. PMID: 23101480 Free PMC article. Clinical Trial.
A multicenter, randomized, open-labeled study to steer immunosuppressive and antiviral therapy by measurement of virus (CMV, ADV, HSV)-specific T cells in addition to determination of trough levels of immunosuppressants in pediatric kidney allograft recipients (IVIST01-trial): study protocol for a randomized controlled trial.
Ahlenstiel-Grunow T, Koch A, Großhennig A, Frömke C, Sester M, Sester U, Schröder C, Pape L. Ahlenstiel-Grunow T, et al. Among authors: koch a. Trials. 2014 Aug 15;15:324. doi: 10.1186/1745-6215-15-324. Trials. 2014. PMID: 25127887 Free PMC article. Clinical Trial.
Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study.
Deterding K, Spinner CD, Schott E, Welzel TM, Gerken G, Klinker H, Spengler U, Wiegand J, Schulze Zur Wiesch J, Pathil A, Cornberg M, Umgelter A, Zöllner C, Zeuzem S, Papkalla A, Weber K, Hardtke S, von der Leyen H, Koch A, von Witzendorff D, Manns MP, Wedemeyer H; HepNet Acute HCV IV Study Group. Deterding K, et al. Among authors: koch a. Lancet Infect Dis. 2017 Feb;17(2):215-222. doi: 10.1016/S1473-3099(16)30408-X. Epub 2016 Oct 28. Lancet Infect Dis. 2017. PMID: 28029529 Clinical Trial.
2,974 results